TBD 201
Alternative Names: TBD-201Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator FibroGenesis
- Class Fibroblast cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA
- 21 Oct 2020 FibroGenesis has patents pending for fibroblast cell therapy technologies for the treatment of Type 1 diabetes mellitus in USA (FibroGenesis' website, October 2020)
- 21 Oct 2020 Preclinical trials in Type 1 diabetes mellitus in USA (unspecified route) before October 2020 (FibroGenesis' pipeline, October 2020)